Panacea Biotec hits 52-week high after settling patent dispute with Sanofi

Panacea Biotec and Sanofi Healthcare India have entered into the settlement agreement on dispute over a patent infringement hexavalent vaccine.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Panacea Biotec share price was locked in upper circuit in Tuesday's trading session after the company announced that it has entered into a settlement agreement with Sanofi Healthcare India over patent dispute.

The stock touched its 52-week high of Rs 349.79 per share on the NSE, up 5 percent to hit the highest permissible trading limit on Tuesday. In fact, the stock has been gaining for the last 8 days on the NSE and has risen 46.51 percent in the period.

Panacea Biotec and Sanofi Healthcare India have entered into the settlement agreement on dispute over a patent infringement for hexavalent vaccine. The company in an exchange filing, said "the parties have reached a settlement agreement, and pursuant to the joint application filed by the Parties, the said suit has been disposed of by the Hon’ble Delhi High Court on September 13, 2024, in terms of the settlement agreement entered between the Parties."

The dispute began when Sanofi received marketing approval for a Shan6 by the Drugs Controller General (India). Panacea Biotec filed a suit before the Delhi High Court seeking to restrain Sanofi Healthcare that would infringe the company’s patent for its EasySix. EasySix is the first innovative fully-liquid hexavalent vaccine from India which is protected by patents in several countries including India.

Sanofi has agreed that it will not directly or indirectly commercially launch its fully liquid hexavalent vaccine Shan6 in India and would withdraw its patent oppositions against Panacea Biotec’s hexavalent vaccine

"Panacea Biotec has also agreed to forego its claim for damages and rendition of accounts in the proceedings against Sanofi as prayed for in the suit," the company said in a statement.

Panacea Biotec shares have delivered multibagger returns of 102.46 percent in 2024 so far, as per BSE data. In the las two years, the shares moved higher by 155.24 percent.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.